A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Adults in good general health
Participants who are 18 to 50 years of age
Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study
Individuals who are pregnant or breastfeeding
Bleeding disorder that was diagnosed by a physician
Infectious disease: Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B infection, current hepatitis C infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.
International AIDS Vaccine Initiative
Lead sponsor
Biomedical Advanced Research and Development Authority
Collaborator